Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | KCNQ3 | O43525 | 12/20 | 0.55 |
| ▸ | KCNQ2 | O43526 | 12/20 | 0.55 |
| ▸ | KCNE1 | P15382 | 9/20 | 0.55 |
| ▸ | KCNQ1 | P51787 | 9/20 | 0.55 |
| ▸ | BACE1 | P56817 | 1/20 | 0.54 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3306012 | 0.84 | KDM4E (0.62) | ALDH1A1KCNQ3KCNQ2KCNE1KCNQ1 | |
| SCHEMBL5618326 | 0.83 | ALDH1A1 (0.57) | ALDH1A1KCNQ3KCNQ2KCNE1KCNQ1 | |
| SCHEMBL12182424 | 0.83 | ALDH1A1 (0.57) | ALDH1A1KCNQ3KCNQ2KCNE1KCNQ1 | |
| SCHEMBL30568974 | 0.80 | KCNQ3 (0.64) | ALDH1A1KCNQ3KCNQ2KCNE1KCNQ1 | |
| SCHEMBL6361424 | 0.80 | KCNQ3 (0.64) | ALDH1A1KCNQ3KCNQ2KCNE1KCNQ1 | |
| SCHEMBL7930779 | 0.79 | HDAC1 (0.48) | HDAC1HDAC6 | |
| SCHEMBL7930570 | 0.79 | HDAC1 (0.48) | HDAC1HDAC6 | |
| SCHEMBL9188646 | 0.79 | ALDH1A1 (0.53) | ALDH1A1KCNQ3KCNQ2KCNE1KCNQ1 | |
| SCHEMBL2436172 | 0.78 | KCNQ3 (0.67) | ALDH1A1KCNQ3KCNQ2KCNE1KCNQ1 | |
| SCHEMBL16061441 | 0.78 | HDAC3 (0.68) | ALDH1A1KCNQ3KCNQ2HDAC1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110190285-A1 | METHODS OF TREATING A BOTULINUM TOXIN RELATED CONDITION IN A SUBJECT | ABSOLUTE SCIENCE, INC. (US) | 2011-08-04 | — | — | US | disclosed |
| US-20110034521-A1 | COMPOUNDS AND METHODS FOR TREATING ZINC MATRIX METALLOPROTEASE DEPENDENT DISEASES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-02-10 | — | — | US | disclosed |
| WO-2010033360-A1 | METHODS OF TREATING A BOTULINUM TOXIN RELATED CONDITION IN A SUBJECT | 1/3 ABSOLUTE SCIENCE, INC. (US) | 2010-03-25 | — | — | WO | disclosed |
| WO-2009045761-A1 | COMPOUNDS AND METHODS FOR TREATING ZINC MATRIX METALLOPROTEASE DEPENDENT DISEASES | ABSOLUTE SCIENCE, INC. (US) | 2009-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034521-A1 | COMPOUNDS AND METHODS FOR TREATING ZINC MATRIX METALLOPROTEASE DEPENDENT DISEASES | MMP7, MMP3, MMP9 | ALDH1A1 496/4885KCNQ3 2598/4885KCNQ2 2627/4885 |
| US-20110190285-A1 | METHODS OF TREATING A BOTULINUM TOXIN RELATED CONDITION IN A SUBJECT | NPY5R, RAC3, CPA3 | ALDH1A1 2213/4885KCNQ3 961/4885KCNQ2 1172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.